Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

949
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
949
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.2K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.3K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.6K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidimensional mechanisms of occupational stress among healthcare workers: a structural equation modeling analysis from the seventh Guangxi health service survey.

Frontiers in psychology·2026
Same author

Emotional Dysregulation-Mediated Associations Between Guilt Proneness, Shame Proneness, and Internet Gaming Disorder Among Chinese University Students: Cross-Sectional Survey.

Journal of medical Internet research·2025
Same author

The association between a stress-is-enhancing mindset and internet gaming disorder was mediated by behavioral disengagement among medical undergraduate students: a multi-center survey in China.

BMC psychiatry·2025
Same author

Association between functional disability and mental health among Chinese older adults: Examining the moderating effects of social participation and physical exercise.

Archives of public health = Archives belges de sante publique·2024
Same author

Extracellular Vesicles Mimetic Design of Membrane Chimeric Nanovesicles for dsRNA Delivery in Spray-Induced Gene Silencing for Crop Protection.

ACS nano·2024
Same author

Social environment, health cognition, and health behavior: how individuals with non-fixed employment end up with adverse health outcomes in China under the era of VUCA?-findings from PLS-SEM and fsQCA.

Frontiers in public health·2024

Related Experiment Video

Updated: Mar 28, 2026

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

3.0K

Losigamone add-on therapy for partial epilepsy.

Yousheng Xiao1, Man Luo, Jin Wang

  • 1Department of Neurology, The First Affiliated Hospital, Guangxi Medical University, No. 22, Shuang Yong Lu, Nanning, Guangxi, China, 530021.

The Cochrane Database of Systematic Reviews
|December 15, 2015
PubMed
Summary

Losigamone effectively reduces seizure frequency in partial epilepsy patients but increases treatment withdrawal and adverse events like dizziness. Further high-quality, long-term studies are needed to confirm its efficacy and safety profile.

More Related Videos

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

13.1K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K

Related Experiment Videos

Last Updated: Mar 28, 2026

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study
11:29

Anteromesial Temporal Lobectomy for Medically Intractable Temporal Lobe Epilepsy: An Operative Study

Published on: August 15, 2025

3.0K
Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

13.1K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Epilepsy affects 50 million globally, with many requiring multiple antiepileptic drugs (AEDs).
  • Losigamone is a newer AED investigated for add-on therapy in partial epilepsy.
  • This review updates previous findings on losigamone's efficacy and safety.

Purpose of the Study:

  • To evaluate the efficacy and safety of losigamone as an add-on treatment for partial epilepsy.
  • To analyze seizure frequency reduction, seizure freedom, and adverse events associated with losigamone.

Main Methods:

  • Systematic review of randomized controlled trials comparing losigamone with placebo.
  • Searched Cochrane Epilepsy Group Register, CENTRAL, and MEDLINE databases.
  • Primary outcomes: >=50% seizure reduction and seizure freedom; secondary outcomes: treatment withdrawal and adverse events.

Main Results:

  • Two trials (467 patients) assessed losigamone (1200-1500 mg/day) as add-on therapy.
  • Losigamone significantly increased 50% seizure reduction (RR 1.76) but also treatment withdrawal (RR 2.16).
  • Adverse events were more frequent (RR 1.34), with dizziness being significant (RR 3.82); higher doses increased efficacy but also dropouts.

Conclusions:

  • Losigamone reduces seizure frequency in partial epilepsy but is linked to increased treatment withdrawals and adverse events.
  • Included trials were short-term with uncertain quality, necessitating longer, high-quality studies.
  • No new studies have emerged since the previous review update.